KOSDAQBiotech & Pharma036220

Osang Healthcare

₩4,190▲ 0.96%2026-11-18 close
Market Cap
₩60B
Turnover
₩32,130,410
Volume
7.7K
Shares out.
14.3M
PER
—
PBR
0.2×
EPS
-₩1,624
Dividend Yield
4.54%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩200 per share · Prices as of the 2026-11-18 close

01

Report overview

Immunoassay Rebound Faded as Losses Return in 2026

Osang Healthcare returned to profit in 2025, but revenue has fallen for three straight quarters in 2026 and operating losses have persisted, so seasonal respiratory-kit demand and new product launches are the key items to track for a recovery.

  1. 1

    The 2025 annual filing shows revenue of KRW 128.6 billion, up 59.8% from the prior year, and operating profit of KRW 2.43 billion, turning positive from the 2024 operating loss of KRW 24.8 billion.

  2. 2

    Third-quarter 2026 revenue was KRW 18.9 billion, down 26.0% year on year, and the net loss attributable to controlling shareholders reached KRW 10.9 billion after a KRW 3.01 billion profit a year earlier.

  3. 3

    Over the latest four quarters, the net loss attributable to controlling shareholders totaled KRW 22.3 billion, and operating losses have continued for five consecutive quarters since the third quarter of 2025.

  4. 4

    In its value-up plan disclosed in March 2026, the company set targets of KRW 300 billion in revenue and an operating margin of 10% or more by 2030.

  5. 5

    As of March 2026, blood glucose meters (51%) and immunoassay products (31%) together account for 82% of revenue, within an export-heavy structure.

02

Business structure

Osang Healthcare is a diagnostics company founded in 1996 whose main lines are biochemical testing (blood glucose and HbA1c meters), immunoassays such as respiratory virus combo kits, and PCR-based molecular diagnostics.

A JobKorea breakdown as of March 2026 shows blood glucose meters at 51%, immunoassays at 31%, HbA1c meters at 13%, molecular diagnostics at 3%, and other products at 2%.

Immunoassays were 82.2% of sales in the 2023 provisional breakdown cited in a 2024 IPO research note, so the mix has shifted back toward glucose meters. The COVID-19, influenza A and B combo kit sold in the United States drove the immunoassay recovery in 2025, according to the company.

The company has said that 97.4% of sales in the first nine months of 2023 came from exports, with the United States at 86.6%, so overseas exposure is high. It sells through regional distributors it set up directly to reduce intermediate layers.

Its glucose meter strip business is expanding local production in Africa and the Middle East through partners in developing markets. Next-generation products include a combo kit adding RSV detection and a continuous glucose monitor (CGM) still in development.

In May 2026 a PCR-based respiratory virus diagnostic platform project was selected for KRW 2.2 billion over three years under a national R&D program.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩25.5B-₩4.9B−19.1%
2025Q4₩29B-₩3.2B−11.0%
2026Q1₩22.9B-₩4.4B−19.2%
2026Q2₩19.1B-₩8.1B−42.2%
2026Q3₩18.9B-₩5B−26.4%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩193.9B₩49.3B₩40.6B25.4%20.3%24.7%
2023₩355.8B₩142.8B₩116.4B40.1%39.7%9.3%
2024₩80.5B-₩24.8B-₩11.4B−30.8%−4.0%3.1%
2025₩128.6B₩2.4B₩3.1B1.9%1.1%19.5%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-14

04

Earnings analysis

On the annual filings, revenue rose from KRW 193.9 billion in 2022 to KRW 355.8 billion in 2023, an 83.5% increase, then fell to KRW 80.5 billion in 2024, a 77.4% decline, before recovering to KRW 128.6 billion in 2025, up 59.8%. Within 2022 to 2025, 2023 was the largest year and 2024 was the smallest.

Operating profit went from KRW 49.3 billion in 2022 to KRW 142.8 billion in 2023, an increase of 189.7%, and the operating margin moved from 25.4% to 40.1%.

In 2024 the company posted an operating loss of KRW 24.8 billion, an operating margin of -30.8%, and in 2025 operating profit was KRW 2.43 billion, an operating margin of 1.9%.

Net profit attributable to controlling shareholders went from KRW 116.4 billion in 2023 to a net loss of KRW 11.4 billion in 2024 and a profit of KRW 3.11 billion in 2025. Consolidated net income including non-controlling interests was KRW 3.11 billion in 2025, a separate figure from the controlling-shareholder line.

The 2023 surge was supported by COVID-19 test kit deliveries, and the 2024 drop reflected weaker immunoassay demand after the shift to endemic conditions.

Quarterly revenue peaked at KRW 29 billion in the fourth quarter of 2025 and then fell to KRW 22.9 billion, KRW 19.1 billion and KRW 18.9 billion over the next three quarters.

Operating losses widened from KRW 4.86 billion in the third quarter of 2025 to KRW 8.08 billion in the second quarter of 2026 before narrowing to KRW 4.99 billion in the third quarter of 2026. The third-quarter 2026 net loss of KRW 10.9 billion compares with a KRW 3.01 billion profit a year earlier.

05

Industry analysis

The recent cycle in the in-vitro diagnostics market is largely a reversal of the COVID-19 demand spike. Immunoassay kit demand surged during the pandemic and lifted sales in 2023, but it fell sharply after the shift to endemic conditions.

The company says its biochemical testing, including glucose meters, regained share of sales as a result. Respiratory diagnostics are highly seasonal, and the company treats the third quarter as a summer off-season and the fourth quarter as the peak season.

The claim that the United States accounts for 40% of the global diabetes testing market comes from the company's own profile material and is cited as the rationale for overseas expansion. In continuous glucose monitoring, the company said it began development in 2017 and, as of 2024, targeted a domestic launch in 2026.

Its competitive strengths are a US emergency use authorization history for a COVID-19 molecular reagent and a directly built export distribution network.

Weaknesses include the sensitivity of immunoassay demand to epidemic cycles and the reliance of glucose meter growth on local production expansion with partners in developing markets.

06

Outlook

In its March 2026 value-up plan, the company targeted sustained revenue growth and an operating margin of 10% or more, and listed KRW 300 billion in revenue by 2030 as a plan item.

On shareholder returns, it adopted a policy of paying dividends at a payout ratio of 25% or more of consolidated net income, and disclosed plans to cancel 200,000 treasury shares in March 2026.

On products, the company said in March 2026 that new products would launch in sequence from that year and that its biochemical diagnostics segment would take a step up. It expects the combo kit to generate stable sales each year around the flu season.

The CGM was targeted for a domestic launch in 2026 when announced in 2024, and the timing of when it will show up in results remains uncertain. The company said a next-generation combo product adding RSV detection is going through clinical and regulatory steps.

In May 2026, its IR page listed a headline on a large supply of HbA1c meters to the Mexican government. The revenue trend needed to reach these targets has moved the other way, with three straight quarterly declines, so the gap between the targets and current results is wide.

07

Valuation

PER
—
PBR
0.2×
ROE
-8.3%
EPS
-₩1,624
BPS
₩18,587
Dividend per share
₩200

Because the last four quarters were net losses, the price-to-earnings ratio cannot be calculated, which shifts the valuation discussion toward net assets and dividends. The price-to-book ratio sits in a range well below book value, and controlling shareholders hold nearly all of the KRW 281.3 billion in equity.

The dividend policy is a payout ratio of 25% or more of consolidated net income, but the losses of 2026 weaken the earnings base behind that policy. The dividend yield is higher than the industry average.

If profits recover after the 2025 turn to profitability, earnings-based multiples may become calculable again, so they can be revisited after the next annual filing. Given that earnings are negative, the direction of results matters more for interpretation than the multiples themselves.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-14

08

Bull factors

2025 return to profit and US combo kit sales

2025 revenue reached KRW 128.6 billion, up 59.8%, and operating profit turned positive at KRW 2.43 billion. The company attributed the improvement to expanded US sales of its combo kit that tests for COVID-19 and influenza A and B at once. It expects the product to generate steady sales in each flu season.

Medium-term targets and shareholder return policy

In its March 2026 value-up plan, the company disclosed a 2030 target of KRW 300 billion in revenue and an operating margin of 10% or more. It also set a dividend policy of a 25% or higher payout ratio on consolidated net income and cancelled 200,000 treasury shares.

Revenue is currently falling against that path, so the route to the targets will need to be confirmed through future results.

Next-generation products and government R&D

A next-generation combo kit adding RSV detection is in development, and the company expects it to carry a higher average selling price than the current kit. In March 2026 the company said new products would launch in sequence from that year.

09

Bear factors

Revenue declines and widening losses in 2026

Quarterly revenue fell to KRW 22.9 billion, KRW 19.1 billion and KRW 18.9 billion across the first three quarters of 2026, and the third quarter was down 26.0% year on year. Operating losses have continued for five consecutive quarters. The net loss attributable to controlling shareholders over the last four quarters totaled KRW 22.3 billion.

Reliance on combo kit and post-endemic volatility

The combo kit that drove the 2025 recovery sells mainly into the flu season, so quarterly revenue is volatile. Revenue fell 77.4% in 2024, and immunoassays were 82.2% of sales in the 2023 provisional breakdown.

The shift to endemic conditions has already shown how quickly immunoassay demand can fall, so the size of any seasonal recovery needs to be confirmed.

Timing of new businesses and overseas investment

Whether the CGM actually launches domestically is the checkpoint that determines when new-product revenue begins to show up. The company invested USD 40 million in US-based Allenz Health and holds a 25% stake as its largest shareholder.

If the value of that investment moves and new-product revenue arrives late, the pace of profit recovery could slow.

10

Risk factors

Seasonality and post-endemic demand swings

Respiratory diagnostics follow a seasonal pattern, with the third quarter a low season and the fourth a peak, so quarterly results swing. Third-quarter 2026 revenue was KRW 18.9 billion, down 26.0% year on year. A smaller epidemic would cut immunoassay demand, which makes flu-season volumes the key variable.

Overseas concentration, currency and regulation

The company has said that 97.4% of sales in the first nine months of 2023 were exports, with the United States at 86.6%. The business depends on US sales and local approvals, so changes in local rules or customs conditions would affect revenue directly. Export sales are also exposed to currency movements.

New product approvals and investment assets

The next-generation combo kit and the CGM are both still going through clinical and regulatory steps. Delays in approval would weigh on the path to the 2030 revenue target. The stake in Allenz Health can move in book value alongside results, which keeps it a variable for the financial position.

11

What to watch next

  1. December 2026 to February 2027

    This is the window to see whether US combo kit sales in the flu season break the three-quarter revenue decline. The company has projected steady sales centered on the flu season.

  2. Around March 2027

    The 2026 annual business report is due, allowing a check on full-year revenue, operating margin and progress toward the 2030 targets. The 2025 results were disclosed on March 10, 2026.

  3. Around May 15, 2027

    This is the deadline for the first-quarter 2027 report, a check on whether revenue recovers and the operating loss narrows compared with the KRW 22.9 billion revenue and KRW 4.39 billion operating loss of the first quarter of 2026.

  4. Anytime from November 2026 onward (timing undetermined)

    Watch for a domestic launch of the CGM and a launch notice for the next-generation combo kit with RSV detection. Once launch timing is set, the timing of any revenue contribution can be gauged.

12

Overall view

Osang Healthcare's annual filings show a cycle of a 2023 peak (revenue of KRW 355.8 billion and operating profit of KRW 142.8 billion), an operating loss in 2024, and a return to profit in 2025. The 2025 profit was helped by expanded US combo kit sales, but operating profit was only KRW 2.43 billion, far below 2023.

Revenue has fallen for three straight quarters in 2026, operating losses have continued for five consecutive quarters, and the net loss attributable to controlling shareholders over the last four quarters totaled KRW 22.3 billion.

The company has set medium-term targets of KRW 300 billion in revenue, an operating margin of 10% or more and a payout ratio of 25% or more by 2030, but the gap to current results is wide.

Strengths include its directly built export distribution network, a US emergency use authorization track record and a price-to-book ratio in a range well below net assets. Weaknesses include seasonality in immunoassays, concentration in US sales and uncertainty over when new products will reach the market.

The next checkpoints are the 2026 annual business report for full-year revenue and operating margin, combo kit sales during the flu season from late 2026 into early 2027, and the first-quarter 2027 report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. thevc.kr
  2. comp.wisereport.co.kr
  3. osanghc.com
  4. m.news.nate.com
  5. jobkorea.co.kr
  6. m.news.nate.com
  7. newspim.com
  8. newspim.com
  9. m.news.nate.com
  10. medigatenews.com
  11. comp.fnguide.com
  12. m.news.nate.com
  13. pharmnews.com
  14. hankyung.com
  15. comp.fnguide.com
  16. eugenefn.com
  17. pharm.edaily.co.kr
  18. pharmnews.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis